Skip to main content
S. 898 117th Congress Senate

Fair Accountability and Innovative Research Drug Pricing Act of 2021

Official title: A bill to require reporting regarding certain drug price increases, and for other purposes.

Introduced: June 9, 2021 Introduced by: Tammy Baldwin Democratic · Wisconsin See on congress.gov
Health Business recordsCivil actions and liabilityCongressional oversightConsumer affairs
More subjectsShow fewer subjects
Corporate finance and managementGovernment information and archivesGovernment studies and investigationsHealth care costs and insuranceInflation and pricesManufacturingMarketing and advertisingMedical researchPrescription drugsResearch and development
Sign in to write a letter Sign in to watch
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 23, 2021
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Mar 23, 2021
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action March 23, 2021

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Plain-English summary Congressional Research Service

Fair Accountability and Innovative Research Drug Pricing Act of 2021

This bill requires manufacturers to report about certain price increases for prescription drugs and biological products with a wholesale cost of at least $100 per month. Such reports must include, among other information (1) the percentage price increase, (2) a justification for such increase, (3) the price history of the drug, (4) the total cost to develop the drug, and (5) the total revenue and net profit generated from the drug.

 Related & companion bills 2
  • HR 19 Lower Costs, More Cures Act of 2021
  • HR 9655 Medicare for America Act of 2019
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 4
All 4 Democratic 1 Republican 2 Independent 1
R
Hoeven, John
North Dakota · Jun 9, 2021
 I
King, Angus S., Jr.
Maine · Jun 9, 2021
 R
Murkowski, Lisa
Alaska · Mar 23, 2021
 D
Smith, Tina
Minnesota · Mar 23, 2021
Cite this page click to expand
APA
U.S. Congress. (2026). S. 898: Fair Accountability and Innovative Research Drug Pricing Act of 2021. 117th Congress. Open America. https://openamerica.io/bill/117-S-898/
MLA
"S. 898: Fair Accountability and Innovative Research Drug Pricing Act of 2021." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-S-898/.
Bluebook (legal)
S. 898, 117th Cong. (2026), https://openamerica.io/bill/117-S-898/.
Markdown link
[S. 898: Fair Accountability and Innovative Research Drug Pricing Act of 2021](https://openamerica.io/bill/117-S-898/)
Report a problem